Researchers have found that treatment with an immunotherapy drug is superior to standard chemotherapy for children with leukemia that has relapsed. The findings, based on a clinical trial, focused on the immunotherapy drug blinatumomab. Subjects in the trial were children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.… Continue reading Immunotherapy Better than Chemotherapy for Some Kids with Leukemia
Tag: immunotherapy
Breaking News: First Immunotherapy Success for Triple-Negative Breast Cancer
Research led by Queen Mary University of London and St Bartholomew’s Hospital in London shows for the first time that a combination of immunotherapy and chemotherapy can tune the body’s own immune system to attack triple-negative breast cancer, extending survival by up to ten months. This discovery holds out new hope for people with an… Continue reading Breaking News: First Immunotherapy Success for Triple-Negative Breast Cancer
The Latest on Melanoma Treatments
Editor’s Note: According to the American Academy of Dermatology (AAD), melanoma is the deadliest form of skin cancer, accounting for approximately 75 percent of skin cancer deaths (1). Approximately 9,940 U.S. residents are expected to die from this disease in 2015 (2). Melanoma is highly treatable when detected early, but survival rates decline for patients… Continue reading The Latest on Melanoma Treatments
Immunotherapy in Early-Stage Breast Cancer
Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials.